Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have given written consent before any trial procedures begin
• Women between 18 and 75 years old
• Women with stage III or IV ovarian cancer (including those who have not had surgery), confirmed by tissue testing to be high-grade serous ovarian cancer
• People who have at least one tumour that can be measured on a scan, as defined by standard medical measurement guidelines (RECIST 1.1)
• People who agree to provide a stored or freshly collected tumour tissue sample for testing
• People with a general health and activity score of 0 or 1 on the ECOG scale (meaning fully active or able to carry out light work)
• People with an expected survival of 6 months or more
• People whose blood and organ function test results meet all of the following minimum levels (confirm with trial site):
  • Haemoglobin (red blood cell measure) at or above 90 g/L
  • Neutrophil count (a type of white blood cell) at or above 1.5 × 10⁹/L, or total white blood cell count at or above 3 × 10⁹/L
  • Platelet count at or above 90 × 10⁹/L
  • Two liver enzyme levels (AST and ALT) each at or below 2.5 times the upper limit of the normal range
  • Total bilirubin (a liver marker) at or below 1.5 times the upper limit of the normal range
  • Creatinine (a kidney marker) at or below the upper limit of the normal range
• Women who could potentially become pregnant must have a negative pregnancy test (blood or urine) within 7 days before joining the trial
• Women who could potentially become pregnant must be willing to use medically approved contraception throughout the trial

Who may not be able to join:

• People diagnosed with another cancer (other than certain fully treated skin cancers) within the 5 years before starting the trial
• People currently taking part in another clinical trial involving an investigational treatment, or who received such a treatment within 4 weeks before starting
• People who have previously received pelvic radiotherapy, systemic chemotherapy, targeted therapy, or immunotherapy for ovarian cancer
• People with brain metastases (cancer spread to the brain) that require treatment, or with signs of spinal cord compression
• People currently taking oral or intravenous beta-blocker medications (such as atenolol, metoprolol, carvedilol, or similar), or people for whom the use of propranolol (a beta-blocker used in this trial) would not be safe
• People who are currently taking propranolol or who stopped taking it less than 14 days before joining (those who stopped 14 or more days before may be considered, subject to the investigator's assessment)
• People who have a medical reason that makes beta-blocker medications unsafe for them, as listed in the propranolol prescribing information
• People who are taking systemic steroid medications or other immune-suppressing treatments within 7 days before starting the trial (low physiological doses of steroids equivalent to 10 mg/day or less of prednisone may be permitted — confirm with trial site)
• People who have received an organ transplant from another person (except corneal transplants) or a stem cell transplant from another person
• People with a known allergy to propranolol hydrochloride or any of its ingredients
• People who have not fully recovered from side effects or complications of a previous treatment (side effects must be at grade 1 or lower, except for tiredness or hair loss)
• People with a known history of HIV infection
• People with known hepatitis B
• People with active hepatitis C infection (confirmed by positive antibody test and detectable virus levels)
• People who received a live vaccine within 30 days before the first dose
• Women who are pregnant or breastfeeding
• People with serious or uncontrolled medical conditions, including:
  • Significant heart rhythm or electrical conduction problems on a resting ECG, such as complete left bundle branch block, second-degree or higher heart block, ventricular arrhythmia, or atrial fibrillation
  • Unstable angina, congestive heart failure, or chronic heart failure classified as grade 2 or higher by the New York Heart Association
  • A heart attack, stroke, transient ischaemic attack, or other arterial blood clot or blockage event within the 6 months before joining
  • A history of pneumonia requiring steroid treatment within the past year, currently active interstitial lung disease, or active tuberculosis
  • An active or uncontrolled infection requiring systemic treatment
  • Active diverticulitis, abdominal abscess, or bowel obstruction
  • Liver disease such as cirrhosis, decompensated liver disease, or active hepatitis
  • A mental health condition that would prevent cooperation with treatment
• People with any other medical history, abnormal test results, or conditions that the trial investigator considers may interfere with the trial or make participation unsafe

Important: Always verify eligibility with the trial site directly before applying.